Complexa names Francisco Salva as CEO, president

Closely-held Complexa appointed Francisco Salva as the company’s new CEO and president, effective immediately.

Mr. Salva will build on the company’s progress to date by further advancing the Phase 2 clinical development of its lead compound, CXA-10, in two orphan indications: pulmonary arterial hypertension and focal segmental glomerulosclerosis. He will also focus on the development of the next-generation of nitrated fatty acid compounds to support the growth of the company.

Most recently, Mr. Salva served as a founder and VP of operations for Acerta Pharma, where he focused on growth initiatives culminating in a $4-billion investment by AstraZeneca for a controlling ownership interest.

“We look forward to Francisco leading Complexa during this critical time in our growth as we advance our lead compound, CXA-10, in Phase 2 clinical development to help patients suffering from debilitating and life-threatening diseases,” David Mott, chairman, said in a statement.

Mr. Salva said he looks forward to joining the Complexa management team, initiating the Phase 2 clinical development of CXA-10 and finding solutions to transform the lives of patients suffering from fibrotic and inflammatory diseases.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.